A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)	Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm	Recruiting	Phase 1	2026-02-25		NCT06521554

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nuvalent Inc.	4

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chris O'Brien Lifehouse	Camperdown	Australia	1
City of Hope - Lennar	Irvine	United States	4
Cross Cancer Institute	Edmonton	Canada	146
Fred Hutchinson Cancer Center	Seattle	United States	250
Georgetown University Medical Center	Washington D.C.	United States	62
Henry Ford Cancer Center	Detroit	United States	1
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center	Baltimore	United States	1
Massachusetts General Hospital	Boston	United States	1015
Memorial Sloan Kettering Cancer Center	New York	United States	1000
NEXT Virginia	Fairfax	United States	83
North Shore Health Hub	Saint Leonards	Australia	1
OSU Brain and Spine Hospital	Columbus	United States	1
Princess Margaret Cancer Center - University Health Network	Toronto	Canada	1
Sarah Cannon Research Institute at HealthOne	Denver	United States	34
Scri Oncology Partners	Nashville	United States	156
Sibley Memorial Hospital	Washington D.C.	United States	121
Stanford Cancer Institute	Stanford	United States	19
Sylvester Comprehensive Cancer Center	Miami	United States	37
The University of Texas MD Anderson Cancer Center	Houston	United States	207
University of California, Davis Comprehensive Cancer Center	Sacramento	United States	18
Washington University	St Louis	United States	182

Clinical trials